In a similar experimental model, HD significantly decreased hepatic TGFβ1, hydroxyproline, the serum liver function markers of ALT, AST and total bilirubin, the hepatic content of MDA and myeloperoxidase activity, the serum pro-inflammatory cytokine TNF-α, relative liver weight, and the serum lipid profile markers cholesterol, triglycerides and low-density lipoprotein compared with the reference drug SL, which suggested that HD may be a promising protective agent against liver fibrosis (Abdel-Sttar et al., 2017). This evidence concerns the gene TGFB1 and Hepatic fibrosis.